Suchergebnisse - "McInnes, Iain B"

PubPharm (747)

11

Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison

enthalten in: Rheumatology and therapy | 2024

von Mease, P. | Warren, R. | Nash, P. | +6

12

Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA) : a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial

enthalten in: Lancet (London, England) | 2024

von Cope, A. | Jasenecova, M. | Vasconcelos, J. | +70

13

Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors : 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL

enthalten in: RMD open | 2024

von Coates, L. | Landewé, R. | McInnes, I. | +15

14

Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis

enthalten in: Rheumatology and therapy | 2024

von Curtis, J. | McInnes, I. | Rahman, P. | +10

15

Advances abound in immune mediated inflammatory diseases

enthalten in: Seminars in arthritis and rheumatism | 2024

von Gravallese, E. | McInnes, I.

16

Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis

enthalten in: Rheumatology (Oxford, England) | 2024

von McGonagle, D. | Kavanaugh, A. | McInnes, I. | +8

ErratumIn: Rheumatology (Oxford). 2024 Mar 28;:. - PMID 38546125

17

Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis : post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study

enthalten in: BMC rheumatology | 2024

von Coates, L. | Rahman, P. | Mease, P. | +7

18

Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study

enthalten in: BMC Rheumatology | 2024

von Coates, L. | Rahman, P. | Mease, P. | +7

19

IL-23 past, present, and future : a roadmap to advancing IL-23 science and therapy

enthalten in: Frontiers in immunology | 2024

von Krueger, J. | Eyerich, K. | Kuchroo, V. | +9

20

Liposomal AntagomiR-155-5p Restores Anti-Inflammatory Macrophages and Improves Arthritis in Preclinical Models of Rheumatoid Arthritis

enthalten in: Arthritis & rheumatology (Hoboken, N.J.) | 2024

von Paoletti, A. | Ly, B. | Cailleau, C. | +18